Analysis by Therapeutic Group (Neuromuscular Blockers, and Spasmolytic); by Formulation (Cyclobenzaprine, Carisoprodol, Chlorzoxazone, and Others); by Route of Administration (Oral, Injectable, and Others); and by End-User (Hospital Pharmacy, Retail Pharmacy, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023 - 2033
Buy Now
The global muscle relaxant drugs market is estimated to garner a revenue of ~USD 3 million by the end of 2033 by growing at a CAGR of ~7% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 6 million in the year 2022. The growth of the market can primarily be attributed to the rising number of populations suffering from musculoskeletal conditions worldwide, along with patients with lower back pain. As per recent statistics provided by the Global Burden of Disease (GBD) in the year 2019, more than 1.71 billion people live with musculoskeletal conditions around the globe.
Get more information on this report:Request Sample PDF
A common problem noticed worldwide is deteriorating muscle health and an increase in muscle spasms. An upsurge in problems such as muscle cramps, sprains and strains, fibromyalgia, tendinitis, neuromuscular disorders, and many more diseases has been observed worldwide.
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~7% |
|
Base Year Market Size (2022) |
~ USD 3 Million |
|
Forecast Year Market Size (2033) |
~ USD 6 Million |
|
Regional Scope |
|
Growth Drivers
Increasing Sedentary Lifestyle and Decreasing Activity Levels – is a crucial reason amongst all other reasons responsible for increasing muscle weakness and musculoskeletal diseases, and is expected to drive the demand for muscle relaxant drugs in the projected period. For instance, global estimates show 81% of adolescents and 1 in 4 adults do not indulge in enough physical activity. Levels of inactivity in economically developed countries are as high as 70%.
Rising Number of Patients with Lower Back Pain - according to the World Health Organization, 570 million people are suffering from low back pain worldwide, contributing to 7.4% of years lived with disability (YLDs) across the globe.
Upsurge in the Number of People Suffering from Osteoarthritis (OA) – it was found that there were 527.81 million prevalent cases of OA globally in 2019.
Growing Geriatric Population - according to the World Health Organization in 2019, there are 1 billion people aged 60 years and older. The number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050.
Rising Number of Cases Related to Fibromyalgia – as per estimates, fibromyalgia affects approximately 4 million US adults, about 2% of the total adult population.
Restrictions on the Use of Muscle Relaxants – which are mostly restricted for pregnant women and alcohol-addicted people. Muscle relaxants when combined with alcohol, may result in confusion, drowsiness, and errors in judgment.
Side effects Associated with Liver Dysfunctional Problems and Respiratory Organs
Short-term Relief Provider
The global muscle relaxant market is segmented and analyzed for demand and supply by therapeutic group into neuromuscular blockers and spasmolytics. Amongst these segments, the neuromuscular blockers segment is anticipated to garner the largest revenue by the end of 2033, backed by the growing number of patients with neuromuscular disorders worldwide, with increasing number of people working remotely. According to the data, between 2019 and 2021, approximately 13 million people were registered every year for neuromuscular diagnosis in the United Kingdom.
The North America muscle relaxant drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033, backed by the upsurge in healthcare expenditure, low physical activity along with the high prevalence of musculoskeletal conditions affecting people of all ages in the region. According to the American Medical Association’s (AMA) Policy Research Perspective (PRP) report, the National Health Expenditures (NHE) increased by 9.7 percent and became 19.7 percent of GDP in the year 2020.
Our in-depth analysis of the global muscle relaxant drugs market includes the following segments:
|
By Therapeutic Group |
|
|
By Formulation |
|
|
By Route of Administration |
|
|
By End-User |
|
AbbVie Inc.
AbbVie Inc., announced the approval of upadacitinib (RINVOQ) for the treatment of active non-radiographic axial spondyloarthritis in patients with signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Antisense Therapeutics Limited- announced a scientific exploration into a new muscle disease indication for ATL1102 – Limb Girdle Muscular Dystrophy R2.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: Upsurge in the use of muscle relaxants with other anaesthetics during surgical procedures, increasing sedentary lifestyle and decreasing levels of activity are the major factors driving the growth of the market.
Ans: The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023 – 2033.
Ans: Side effects associated with other drugs, liver damage, respiratory disorder and use of muscle relaxant drugs as temporary relief provider are estimated to hamper the market growth.
Ans: The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
Ans: The major players in the market are AbbVie Inc., Sandoz International GmbH, Abbott Laboratories, Pfizer, Inc., Merck & Co., Inc., SteriMax Inc., Vertical Pharmaceuticals, LLC, Instas Pharmaceuticals Ltd. and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by therapeutic group, formulation, route of administration, end user and by region.
Ans: The neuromuscular blocker is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
